NRCTC recruiting now!
We are currently recruiting patients to clinical trials for patients with aHUS and C3G. Each has their own specific inclusion criteria.
If you have aHUS or C3G and wish to find out more about studies that might be suitable for you, you or your consultant can contact one of the team at the NRCTC (firstname.lastname@example.org or C3.email@example.com).
NRCTC Investigator-led studies
Members of the NRCTC are also currently running investigator-led studies in the UK. Sites are open throughout the UK. Details can be found on the study websites in the links below.
SETS aHUS (or Stopping Eculizumab Treatment Safely in aHUS) – this is an investigator-led study that is led by Professor Neil Sheerin and the team at Newcastle University to investigate the safety and impact of eculizumab withdrawal in patients with atypical haemolytic uraemic syndrome. Further details of this study are hosted on this website here.
ECUlizumab in Shiga-Toxin producing Escherichia Coli Haemolytic Uraemic Syndrome (ECUSTEC) : A Randomised, Double-Blind, Placebo-Controlled Trial – this is an investigator-led study by Dr. Sally Johnson to investigate whether ecuilzumab reduces the severity of STEC-HUS in children and young people. Further details of this study can be found here.
Details of all clinical trials in either aHUS or C3G, can be found at the www.clinicaltrials.gov website at the following links.